| Literature DB >> 26944921 |
Kendall Morrison1, Pia M Challita-Eid2, Arthur Raitano2, Zili An2, Peng Yang2, Joseph D Abad2, Wendy Liu2, Dawn Ratay Lortie2, Josh T Snyder2, Linnette Capo2, Alla Verlinsky2, Hector Aviña2, Fernando Doñate2, Ingrid B J Joseph2, Daniel S Pereira2, Karen Morrison2, David R Stover2.
Abstract
SLITRK6 is a member of the SLITRK family of neuronal transmembrane proteins that was discovered as a bladder tumor antigen using suppressive subtractive hybridization. Extensive immunohistochemistry showed SLITRK6 to be expressed in multiple epithelial tumors, including bladder, lung, and breast cancer as well as in glioblastoma. To explore the possibility of using SLITRK6 as a target for an antibody-drug conjugate (ADC), we generated a panel of fully human mAbs specific for SLITRK6. ADCs showed potent in vitro and in vivo cytotoxic activity after conjugation to Monomethyl Auristatin E or Monomethyl Auristatin F. The most potent ADC, ASG-15ME, was selected as the development candidate and given the product name AGS15E. ASG-15ME is currently in phase I clinical trials for the treatment of metastatic urothelial cancer. This is the first report that SLITRK6 is a novel antigen in bladder cancer and also the first report of the development of ASG-15ME for the treatment of metastatic bladder cancer. Mol Cancer Ther; 15(6); 1301-10. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26944921 DOI： 10.1158/1535-7163.MCT-15-0570
Source DB: PubMed Journal: Mol Cancer Ther ISSN： 1535-7163 Impact factor: 6.261